Amicus Therapeutics Inc's Customers Performance

Name: Amicus Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

FOLD

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


FOLD's Source of Revenues		During the corresponding time, Amicus Therapeutics Inc recorded a revenue increase by 23.72 % year on year, sequentially revenue grew by 9.86 %. While revenue at the Amicus Therapeutics Inc 's corporate clients • List of FOLD Customers

for the same period Amicus Therapeutics Inc recorded revenue increase by 23.72 % year on year, sequentially revenue grew by 9.86 %.

• List of FOLD Customers

Amicus Therapeutics Inc's Business Units


Galafold	82.06 %	of total Revenue
Pombiliti Opfolda	18.22 %	of total Revenue
United States Galafold	33.93 %	of total Revenue
United States Pombiliti Opfolda	7.75 %	of total Revenue
Non-US Galafold	48.13 %	of total Revenue
Non-US Pombiliti Opfolda	10.47 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Amicus Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Amicus Therapeutics inc Contracts

Advancements in Pompe Disease Management New Long-Term Data for Pombiliti and Opfolda Makes Strides in Clinical Effic...

The landscape of Pompe disease management continues to evolve, with the presentation of new four-year data for Pombiliti (cipaglucosidase alfa-atga) in combination with Opfolda (miglustat) at the recent International Congress on Inborn Errors of Metabolism (ICIEM). This latest disclosure adds substantial support to the growing body of evidence underscoring the clinical efficacy and safety profile of this promising therapeutic duo.Pombiliti, a novel enzyme replacement therapy, works in concert with Opfolda, an established oral treatment, to offer a comprehensive approach to addressing the multifaceted challenges of Pompe disease. The recently shared long-term data not only enhances our understanding of the th...

FOLD's Stock Performance relative to it's Customers

FOLD's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Amicus Therapeutics inc	4,468.19	597.49	-14.06	511
SUBTOTAL	0.00	0.00	0.00	-

Sources: Amicus Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Amicus Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Amicus Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.